Non Hodgkin Lymphoma Clinical Trial

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

View Full Description

Full Description

All eligible subjects must be relapsed or refractory to at least 2 prior lines of therapy, one of which must have included an inhibitor of B-cell receptor signaling (approved Bruton's tyrosine kinase inhibitor [BTKi] or Phosphoinositide 3-kinase inhibitor [PI3Ki]) or venetoclax. The dose escalation (Part A) will evaluate the safety, tolerability, and PK of escalating doses of CC-99282 given in combination with intravenous obinutuzumab to determine the MTD and RP2D of CC-99282 when given in combination with obinutuzumab. The dose expansion (Part B) may occur at the MTD established in the dose escalation phase, or at an alternative tolerable dosing schedule, based on review of safety, PK and PD data from Part A.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject is ≥18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

Must have a documented diagnosis of CLL/SLL requiring treatment (IwCLL Guidelines for the Diagnosis and Treatment of CLL). In addition presence of clinically measurable disease determined by at least one of the factors listed:

nodal lesion that measures ≥ 1.5 cm in longest dimension (LD) and ≥ 1.0 cm in longest perpendicular dimension (LPD), or
spleen that measures ≥ 14 cm in longest vertical dimension (LVD) with a minimum of 2 cm enlargement, or
liver that measures ≥ 20 cm in LVD with a minimum of 2 cm enlargement, or
peripheral blood B lymphocyte count > 5000/uL
All eligible subjects must be relapsed after or be refractory to >2 prior lines of therapy one of which must have included an approved BTK inhibitor.

Must meet the following laboratory parameters:

Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3 or ≥ 1000 cells/mm^3 if secondary to bone marrow involvement by disease, without growth factor support for 7 days (14 days if pegfilgastrim).
Platelet count ≥ 75,000 cells/mm^3 (100 x 10^9/L) or ≥ 50,000 cells/mm^3 (50 x 10^9/L) if secondary to bone marrow involvement by disease, without transfusion for 7 days.
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) < 3.0 x upper limit of normal (ULN).
Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome.
Calculated creatinine clearance of ≥ 60 ml/min.

Exclusion Criteria:

Presence of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
Prior allogeneic stem cell transplant (SCT)/bone marrow transplant within 12 months of signing the ICF. Subjects who received allogeneic SCT ≥ 12 months before signing the ICF may be eligible provided there is no ongoing graft-versus-host disease and no ongoing immune suppression therapy.
Subject has received prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to starting CC-99282.
Subject has received prior therapy with CRBN-modulating drug (eg, lenalidomide, avadomide/CC-122, pomalidomide) ≤ 4 weeks prior to starting CC-99282.
History of second malignancies with life expectancy of ≤ 2 years or requirement of therapy that would confound study results.
Peripheral neuropathy ≥ Grade 2.
History of hypersensitivity to lenalidomide, pomalidomide, thalidomide.
Impaired cardiac function or clinically significant cardiac disease.
Persistent diarrhea or malabsorption ≥ NCI CTCAE Grade 2, despite medical management.
Active disease transformation (ie, Richter's Syndrome)
Uncontrolled/active autoimmune hemolytic anemia or thrombocytopenia

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

50

Study ID:

NCT04434196

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Jennifer Brown, Site 106
Contact
617-632-4564
University of Cincinnati Medical Center
Cincinnati Ohio, 45219, United States
University Of Cincinnati Medical Center
Cincinnati Ohio, 45219, United States More Info
John Byrd, Site 108
Contact
614-620-6533
The Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States
Oregon Health and Science University
Portland Oregon, 97201, United States
Southwestern Medical Center- Harold C Simmons Comprehensive Cancer Center
Dallas Texas, 75390, United States
Local Institution - 403
Innsbruck , 6020, Austria More Info
Site 403
Contact
Universitaetsklinik fuer Innere Medizin V
Innsbruck , 6020, Austria
Landeskrankenhaus Salzburg
Salzburg , 5020, Austria
Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien
Wien , 1090, Austria
Princess Margaret Hospital University Health Network
Toronto Ontario, M5G 2, Canada
Sir Mortimer B. Davis - Jewish Genl
Montreal Quebec, H3T 1, Canada
Hospital Universitario Vall D hebron - PPDS
Barcelona , 08035, Spain
Clinica Universidad de Navarra
Madrid , 28027, Spain
Hospital 12 de Octubre
Madrid , 28041, Spain
Clinica Universidad de Navarra
Pamplona , 31008, Spain
Hospital Universitario de Salamanca
Salamanca , 37007, Spain
Hospital Clinico Universitario de Valencia
Valencia , 46010, Spain
Local Institution - 305
Valencia , 46010, Spain More Info
Site 305
Contact

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

50

Study ID:

NCT04434196

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.